Health ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs Medications Drug Development GLP-1 Medications Semaglutide Clinical Trials GLP-1 Agonists Drugs Obesity Treatments Obesity

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Lower-cost semaglutide generics are winning buyers in a price-sensitive market.

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

Lindt Data Shows GLP‑1 Households Buying More, Not Less, Chocolate in the U.S.

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Serena Williams’ Super Bowl Zepbound Ad Draws Criticism Over Weight-Loss Pitch, Ro Connection

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

Trump Cites 'Very Fat' Friend's Ozempic Story to Decry Price Gap

Weight-Loss Pills Could Trim Airline Fuel Costs, Jefferies Says

Strive Compounding Sues Lilly and Novo, Alleging Antitrust Push to Block Compounded GLP-1s

Amazon Pharmacy Adds FDA-Approved Wegovy Pill With $25 Copays and Nationwide Delivery

Eli Lilly, Nimbus Sign AI Discovery Deal for Oral Obesity Drugs

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

Nvidia Reportedly Pauses Intel 18A Chip Tests, Knocking Intel Shares

FDA Approves First Wegovy Pill for Chronic Weight Management

FDA Clears Wegovy Weight-Loss Pill, U.S. Launch Set for January

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal